Pharmacokinetics and individualized medication of intravenous voriconazole in liver transplant recipients

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100052870

Enrollment

Unknown

Registered

2021-11-06

Start date

2021-11-01

Completion date

Unknown

Last updated

2022-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post liver transplantation

Interventions

Voriconazole conventional treatment group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years; 2. Within 1 month after liver transplantation; 3. Receiving intravenous voriconazole.

Exclusion criteria

Exclusion criteria: 1. Application of extracorporeal membrane oxygenation; 2. Concomitant use of strong CYP450 enzyme inhibitors or inducers; 3. Absence of important dosing information or voriconazole concentrations or clinical data.

Design outcomes

Primary

Measure	Time frame
Plasma voriconazole concentrations;Voriconazole PK parameters;	—

Secondary

Measure	Time frame
Biochemical indices;	—

Countries

China

Contacts

Public ContactCai Changjie

The First Affiliated Hospital of Sun Yat-Sen University

caichjie@mail.sysu.edu.cn+86 13570097848

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026